SIM-0235 is under clinical development by Simcere Pharmaceutical Group and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIM-0235’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIM-0235 overview
SIM-0235 is under development for the treatment of solid tumours, non-small cell lung cancer, metastatic ovarian cancer, metastatic hepatocellular carcinoma and cutaneous T-cell lymphoma. It is administered through intravenous route. The drug candidate is a monoclonal antibody and it acts by targeting tumor necrosis factor receptor (TNFR2).
Simcere Pharmaceutical Group overview
Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company that discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and amlodipine besylate tablets among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low-end generics and APIs for innovative medicines. Simcere is headquartered in Nanjing, Jiangsu, China
For a complete picture of SIM-0235’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
